FTY720 Phosphate Catalog No.:M22736-C At the moment Phase III

At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)

4-oxadiazol-3-yl}-1H-indol-1-yl)butanoic acid

49(2):264-74

Lawrence R

FTY720 Phosphate Catalog No.:M22736-C At the moment Phase IIIFTY720 is sphingosine 1 phosphate (S1P) receptors agonist . FTY720 is a novel immunomodulatory agent derived from ISP 1 (myriocin), a fungal metabolite that exists in traditional Chinese herbal medicine. In higher eukaryotes, S1P is the ligand for five G protein coupled receptors. These S1P receptors are differentially expressed and regulate vascular maturation, angiogenesis, cardiac development and immunity. S1P receptors are important for directed